Biocon Biologics Revenue and Competitors
Estimated Revenue & Valuation
- Biocon Biologics's estimated annual revenue is currently $750M per year.
- Biocon Biologics's estimated revenue per employee is $178,571
Employee Data
- Biocon Biologics has 4200 Employees.
- Biocon Biologics grew their employee count by 6% last year.
Biocon Biologics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate VP ( Global Head Quality Control ) | Reveal Email/Phone |
2 | Associate VP | Reveal Email/Phone |
3 | VP | Reveal Email/Phone |
4 | Associate VP | Reveal Email/Phone |
5 | VP - Business Finance | Reveal Email/Phone |
6 | Head - Metabolic Business | Reveal Email/Phone |
7 | AVP - Head Key Accounts | Reveal Email/Phone |
8 | Head QA Biocon Biologics | Reveal Email/Phone |
9 | VP Operations | Reveal Email/Phone |
10 | VP -Global Head IPR (Chief IP counsel) | Reveal Email/Phone |
What Is Biocon Biologics?
Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company. Biocon Biologics is engaged in developing high quality, affordable biosimilars that can expand access to a cutting-edge class of therapies to patients globally. It is uniquely positioned as a fully integrated ‘pure play' biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in at least one of the developed markets of EU, U.S. and Japan. Biocon Biologics has a product pipeline of 28 molecules, including 11 with Mylan, several with Sandoz and is developing many independently. Biocon Biologics believes that strong partnerships offer enormous opportunities to co-create the future of healthcare, building a patient ecosystem beyond the product, which can transform millions of lives.
keywords:N/A
N/A
Total Funding
4200
Number of Employees
$750M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Biocon Biologics News
The biosimilar business under Biocon Biologics Ltd had a revenue of Rs 982 crore in the fourth quarter, up 48 per cent from the same period of...
Biocon Sdn. Bhd. a subsidiary of Biocon Biologics in Malaysia, will manufacture and supply its range of insulins to its partner Duopharma...
Biocon Biologics' Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health...
Nov. 3, 2021 Viatris Inc. and Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd., are proud to confirm that Prime Therapeutics, a leading pharmacy benefit manager (PBM) serving nearly 33 million members, will list Semglee® (insulin glargine-yfgn) injection, a branded product, and Insul ...
The Biocon Biologics Manufacturing Plant (B3), the newest addition to the biopharmaceutical company's 100-acre Biocon Park in Bengaluru, India, is no small achievement. Stretching 340,000 square feet and costing $120 million (USD), it is now the largest monoclonal antibodies (mAbs) facility in ...
Other Companies in Bangalore
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $428.5M | 4281 | 15% | $426M |
#2 | $430.5M | 4393 | -1% | $292.9M |
#3 | N/A | 4456 | 7% | N/A |
#4 | $435.2M | 4782 | 5% | $364M |
#5 | $954.8M | 6009 | 8% | N/A |